The company’s POCare cell therapy platform is designed to advance the development of Advanced Therapy Medicinal Products — medicines based on genes, tissues or cells — through collaborations and in-licensing with other companies.
CEO Vered Caplan is confident in the pedigree and resources of the Baltimore research university.
“JHU has unparalleled capabilities in the cell and gene therapy sector,” Caplan said in a statement. Our POCare platform is designed to provide unique cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed systems and other advanced cell processing technologies at the point of care.
“We look forward to utilizing our POCare platform to support JHU’s growing development and processing needs in order to advance and accelerate cell and gene based clinical therapeutic research. We believe this collaboration with JHU, a clear leader in the field of cell and gene therapy, further validates the significant value proposition of our POCare platform.”
Johns Hopkins is the third major institution to sign an agreement with Orgenesis, Caplan said. Last month, the company reached a deal with the University of California, Davis.
With its introduction of Orgenesis’s POCare platform, hospitals are able to implement the company's proprietary automated, closed systems and know-how to collect, process and supply cells for various treatments such as the manufacturing of CAR-T cell therapies.
The Germantown, Maryland-based company provides centralized contract development and manufacturing organization (CDMO) services, as well as localized point-of-care development and processing centers through its subsidiary Orgenesis Maryland Inc.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel